IL6 and inflammatory bowel disease: As a general biomarker of disease activity in IBD, IL-6 adds little to recognized biomarkers like CRP, in line with previous findings [5,33,34], considering that IL-6 is not routinely measured in the clinical setting, its standardization is low and cost is definitely higher than CRP; but it might be potentially linked to nutritional status.